Company / Shareholders' Equity
Xenetic Biosciences, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.0M
FY2025
5-year range
$6.0M / $18.4M
FY2021-FY2025
Trend
-38.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $18M in FY2022 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -19.0%.
Declined from $14M to $6M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -31.1%
- 5-Year CAGR
- -19.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Xenetic Biosciences, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of -19.0%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 38.7% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.0M | -38.7% |
| FY2024 | $9.8M | -28.2% |
| FY2023 | $13.6M | -25.8% |
| FY2022 | $18.4M | +50.6% |
| FY2021 | $12.2M | -29.0% |
| FY2020 | $17.2M | +73.6% |
| FY2019 | $9.9M | -30.7% |
| FY2018 | $14.3M | -11.6% |
| FY2017 | $16.2M | +144.7% |
| FY2016 | $6.6M | -68.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026